Pure Global AI
NCT06137183Not yet recruiting

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)

A Phase II, Multicenter Induction Study With an Active Treatment Extension to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Patients With Moderate to Severe Ulcerative Colitis
Genentech, Inc.Phase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Ulcerative Colitis
Drug/Device/Intervention
Vixarelimab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Genentech, Inc.
Timeline & enrollment
Phase
Phase 2
Start date
Jan 15, 2024
End date
May 01, 2027
Enrollment
210 participants
Primary outcome

Proportion of Participants with Clinical Remission

Summary

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of
 vixarelimab compared with placebo in participants with moderate to severe UC who have
 demonstrated inadequate response to, loss of response to, or intolerance to prior
 conventional or advanced therapy.

ICD-10 classifications
Ulcerative colitisOther ulcerative colitisUlcerative colitis, unspecifiedArthropathy in ulcerative colitisJuvenile arthritis in ulcerative colitis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06137183
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06137183 through Pure Global AI's free database. This Phase 2 trial is sponsored by Genentech, Inc. and is currently Not yet recruiting. The study focuses on Ulcerative Colitis. Target enrollment is 210 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.